EFFECTS Bibliography

Published full papers in peer-reviewed journals. Updated 1 Nov 2023
  1. Tamar Abzhandadze, Erik Lundström, Dongni Buvarp, Marie Eriksson, Terry Quinn, Katharina S Sunnerhagen. Development of a short Swedish version of the Montreal Cognitive Assessment. Journal of Rehabilitation Medicine. 2023 Jun 13:55:jrm4442. DOI: 10.2340/jrm.v55.4442. 
    PMID: 37309231. 
    Impact Factor: 3.5. 
  2. Dongni Buvarp, Adam Viktorisson, Felix Axelsson, Elias Lehto, Linnea Lindgren,  Erik Lundström, Katharina S. Sunnerhagen. Physical Activity Trajectories and Functional Recovery After Acute Stroke Among Adults in Sweden. JAMA Netw Open. 2023;6(5):e2310919. doi:10.1001/jamanetworkopen.2023.10919. 
    Impact Factor: 13.4
  3. Jonathan Tay, EFFECTS Trial Collaboration, Björn Mårtensson, Hugh S Markus, Erik Lundström. Does fluoxetine reduce apathetic and depressive symptoms after stroke? An analysis of the Efficacy oF Fluoxetine-a randomized Controlled Trial in Stroke trial data set. Int J Stroke. 2023 Mar;18(3):285-295. doi: 10.1177/17474930221124760. Epub 2022 Sep 19. PMID: 36050815.
    Impact Factor: 6.9 
  4. Erik Lundström, Eva Isaksson, Nina Greilert Norin, Per Näsman, Per Wester, Björn Mårtensson, Bo Norrving, Håkan Wallén, Jörgen Borg, Gillian Mead, Graeme J Hankey, Maree L Hackett, Martin Dennis , and Katharina S Sunnerhagen. Effects of fluoxetine on outcomes at 12 months after acute stroke. Results from EFFECTS, a randomized controlled trial. Stroke. 2021 Oct 52 (10), pp.3082-3087. PMID: 34465201.
    Impact Factor: 10.2 
  5. Adam Viktorisson, Elisabeth M Andersson, Erik Lundström, Katharina S Sunnerhagen. Levels of physical activity before and after stroke in relation to cognitive function: a prospective study in Sweden. Sci Rep. 2021 Apr 27;11(1):9078. doi: 10.1038/s41598-021-88606-9. Click here.
    Impact Factor: 5.0 
  6. Abzhandadze T, Lundström E, Buvarp D, Eriksson M, Quinn TJ, Sunnerhagen KS. Development of a short-form Swedish version of the Montreal Cognitive Assessment (s-MoCA-SWE): protocol for a cross-sectional study. BMJ Open. 2021 May 3;11(5):e049035. doi: 10.1136/bmjopen-2021-049035. PMID: 33941639; PMCID: PMC8098968.
    Impact Factor: 3.0 
  7. Gillian Mead, Catriona Graham, Laurent Biot, Per Näsman, Erik Lundström, Steff Lewis, Graeme J Hankey, Maree L Hackett, John Forbes, and Martin Dennis on behalf of the FOCUS, AFFINITY and EFFECTS trialists. Update on the statistical analysis plan for an individual patient data meta-analysis (IPDM) for three large trials of fluoxetine for stroke recovery. Trials. 2020 Nov 25;21(1):971. DOI: 10.1186/s13063-020-04875-1. PMID: 33239053. Click here.
    Impact Factor: 2.5
  8. Eva Isaksson, Per Wester, Ann-Charlotte Laska, Per Näsman, and Erik Lundström. Validation of the simplified modified Rankin Scale questionnaire. European Neurology. Eur Neurol. 2020;83(5):493-499. doi: 10.1159/000510721. Epub 2020 Oct 7. PMID: 33027792. Click here.
    Impact Factor: 2.4
  9. Erik Lundström, Eva Isaksson, Per Näsman, Per Wester, Björn Mårtensson, Bo Norrving, Håkan Wallén, Jörgen Borg, Martin Dennis, Gillian Mead, Graeme J Hankey, Maree L Hackett, and Katharina S Sunnerhagen. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2020 Aug;19(8):661-669. Click here.
    Impact Factor: 48.
  10. Ann-Sofie Rudberg, Eivind Berge, Ann-Charlotte Laska, Stina Jutterström, Per Näsman, Katharina S Sunnerhagen, and Erik Lundström. Stroke survivors’ priorities for research related to life after stroke. Topics in Stroke Rehabilitation. 2020; 2020 Jul 5;1-6. DOI: 10.1080/10749357.2020.1789829. PMID: 32627722. Click here.
    Impact Factor: 2.1
  11. Erik Lundström,  Eva Isaksson, Per Näsman, Per Wester, Björn Mårtensson,  Bo Norrving,  Håkan Wallén, Jörgen Borg, Martin Dennis, Gillian Mead,  Graeme J Hankey, Maree Hackett, and Katharina Stibrant Sunnerhagen. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. Trials 2020: 21:233. Click here.
    Impact Factor: 2.5.
  12. Eva Isaksson, Per Wester, Ann-Charlotte Laska, Per Näsman, and Erik Lundström. Identifying important barriers to recruitment of patients in randomised clinical studies using a questionnaire for study personnel. Trials. 2019. 20, 618. Click here.
    Impact Factor: 2.5
  13. Erik Lundström, Eva Isaksson, Per Wester, Ann-Charlotte Laska, and Per Näsman. Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): study protocol for a randomised stepped wedge cluster trial within the EFFECTS trial. Trials 2018 19:14. Click here.
    Impact Factor: 2.5.
  14. Catrion Graham, Steff Lewis, John Forbes, Gillian Mead, Maree L. Hackett, Graeme J. Hankey, John Gommans, Huy Thang Nguyen, Erik Lundström, Eva Isaksson, Per Näsman, Ann-Sofie Rudberg, and Martin Dennis. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials 2017, 18(1):627. PMID 29282099. Click here.
    Impact Factor 2.5.
  15. Gillian Mead , Maree Hackett , Erik Lundström , Veronica Murray , Graeme J Hankey, and Martin Dennis. The FOCUS,AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015 20 (16):369. PubMed PMID:26289352. Click here.
    Impact Factor: 2.5.
Manuscripts 
  • Eva Isaksson, Per Näsman, Per Wester, Ann-Charlotte Laska, Erik Lundström. Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): a stepped wedge cluster randomised trial within the EFFECTS trial. Under review
  • Ann-Sofie Rudberg, Per Näsman, and Erik Lundström. Health-related quality of life (EQ-5D-5L) based on the modified Rankin Scale.
Correspondence since 2013
  • Gillian Mead, Martin Dennis, Erik Lundström, Veronica Murray , Maree L Hackett, and Graeme J Hankey. Letter by Mead. Selective serotonin reuptake inhibitors for stroke:
    more trials are needed. Stroke. 2013 Apr;44(4):e40-1. doi:
    10.1161/STROKEAHA.112.681130. Epub 2013 Jan 22. PubMed PMID: 23339962
Editorials and commentaries on EFFECTS since 2020
  • Gert Kwakkel, Carel G M Meskers, and Nick S Ward. Time for the next stage of stroke recovery trials. Lancet Neurology Volume 19, Issue 8, August 2020, Pages 636-637.
Abstracts published since 2013
  • ESOC 2020. Efficacy of fluoxetine – a randomised controlled trial in stroke (EFFECTS). Presented at a webinar 13 May 2020. EFFECTS and AFFINITY were selected as two of the five highest-rated research works at the joint ESO-WSO Conference. Also presented at Large Clinical Trials , the virtual ESO-WSO Conference, 7 Nov 2020.
  • ESOC 2019. You find the poster here and the Abstract is published in the European Stroke Journal, Abstract number AS-36-014 entitled UPDATE ON THE EFFECTS TRIAL OF FLUOXETINE FOR STROKE RECOVERY: AN INVESTIGATOR-LED RANDOMISED CONTROLLED STUDY IN SWEDEN. European Stroke Journal.  Volume 4 Issue 1_suppl, May 2019. First Published May 22, 2019.
  • ESOC 2016
  • ESOC 2014
PhD students

Ann-Sofie Rudberg

  • Half-time control 12 September 2018 at Karolinska Institutet, Sweden
  • Dissertation 7 May 2021, Karolinska Institutet

Eva Isaksson

  • Half-time control 14 December 2018 at Karolinska Institutet, Sweden
  • Dissertation 19 Mars 2021, Karolinska Instiutet. Preliminary at Danderyds sjukhus at 09:00 (back-up plan ZOOM)

Elias Lindvall

  • Registered Jan 2019 at Uppsala University, Sweden
Publication plan
  1. An individual patient data meta-analysis of the three large fluoxetine for stroke recovery trials. On behalf of the AFFINITY, EFFECTS and FOCUS trialists. Planned submission Dec 2023.
  2. The MAP EFFECTS study. This is an exploratory study of neural mechanisms of fluoxetine mediated motor, cognitive, and language recovery after stroke. We aiming to do a Trial Within a Study (TWIST), using the EFFECTS as the mother study.
Reviews
  • Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Legg LA, Rudberg AS, Hua X, Wu S, Hackett ML, Tilney R, Lindgren L, Kutlubaev MA, Hsieh CF, Barugh AJ, Hankey GJ, Lundström E, Dennis M, Mead GE. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD009286. doi: 10.1002/14651858.CD009286.pub4. PMID: 34780067.
    Impact Factor: 11.9
  • Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.Joshua S Jones, Rina Kimata , Osvaldo P Almeida, Graeme J Hankey. Stroke. 2021 Jun 25; STROKEAHA120032973. doi: 10.1161/STROKEAHA.120.032973. Click here for Abstract.
    Impact Factor: 10.2
Publications from our sister trials FOCUS and AFFINITY
  1. Alexander Chye, Maree Hackett, Graeme Hankey, Erik Lundström, Osvaldo Almeida, John Gommans, Martin Dennis, Stephen Jan, Gillian Mead, Andrew Ford, Christopher Etherton Beer, Leon Flicker, Candice Delcourt, Laurent Billot, Craig Anderson, Katharina Stibrant Sunnerhagen, Qilong Yi, Severine Bompoint, Thang Nguyen, Thomas Lung. Repeated measures of modified Rankin Scale scores to assess functional recovery from stroke: AFFINITY study findings. 10.1161/JAHA.121.025425. Journal of the American Heart Association. 2022;0:e025425. Originally published: 5 Aug 2022. Link to article here.
    Impact Factor: 6.1
  2. Graeme Hankey, Maree Hackett, Osvaldo Almeida, Leon Flicker, Gillian Mead, Martin Dennis, Christopher Etherton Beer, Andrew Ford, Laurent Billot, Stephen Jan, Thomas Lung, Erik Lundström, Katharina Stibrant Sunnerhagen, Craig Anderson, Huy Thang Nguyen, John Gommans, Qilong Yi, AFFINITY Trial Collaboration. Twelve month outcomes of the AFFINITY trial of fluoxetine for functional recovery after acute stroke. Stroke. 2021 Aug;52(8):2502-2509. doi: 10.1161/STROKEAHA.120.033070. Epub 2021 May 21. Click here for Abstract.
    Impact Factor: 10.2
  3. Graeme J Hankey, Maree L Hackey, Osvaldo P. Almeida, Leon Flicker, Gillian E Mead, Martin S. Dennis, Christopher Eheron-Beer, Andre H. Ford, Laren Billo, Sephen Jan, Erik Lundström, Craig S. Anderson, H Thang-Ngen, John Gommans, Qilong Yi, Thomas Lng. Safety and efficacy of fluoxetine on functional recovery after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2020 Aug;19(8) 651-679. Click here.
    Impact Factor: 48
  4. Martin Dennis, John Forbes , Catriona Graham, Maree Hackett , Graeme Hankey, Allan House A, Steff Lewi, Erik Lundström, Peter Sandercock, Gillian Mead. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technology Assessment 2020;24(22). Click here.
    Impact Factor :4.1.
  5. Gillian Mead, Lynn Legg, Russel Tilney, Cheng Fang Hsieh, Simiao Wu, Erik Lundström, Ann Sofie Rudberg, Mansur Kutlubaev, Martin S Dennis, Babak Soleimani, Amanda Barugh, Maree L. Hackett and Graeme J. Hankey. Fluoxetine for stroke recovery: meta-analysis of randomised controlled trials. International Journal of Stroke. Click here.
    Impact Factor: 6.7
  6. Martin Dennis, John Forbes, Catriona Graham, Maree L. Hackett, Graeme J. Hankey, Allan House, Steff Lewis, Erik Lundström, Peter Sandercock, Gillian Mead. Fluoxetine and Fractures After Stroke. Exploratory Analyses From the FOCUS Trial. Stroke. 20 Aug 2019. Click here.
    Impact Factor: 10.2
  7. Abstract and ePoster on fractures and fluoxetine (THE EFFECTS OF FLUOXETINE ON FRACTURE RISK AFTER STROKE – FURTHER ANALYSES FROM THE FOCUS TRIAL)
  8. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. Published online December 5, 2018. Open Access.
    Impact Factor: 169.